Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - REPROS THERAPEUTICS INC.v333152_ex99-1.htm




Washington, D.C. 20549




Current Report Filed Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934


Date of Report

(Date of earliest event reported): January 28, 2013


Repros Therapeutics Inc.

(Exact name of registrant as specified in its charter)


Delaware 001-15281 76-0233274

(State or other jurisdiction of incorporation or organization)


(Commission File Number) (I.R.S. Employer Identification No.)

2408 Timberloch Place, Suite B-7

The Woodlands, Texas 77380

(Address of principal

executive offices

and zip code)


(281) 719-3400

(Registrant’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 7.01Regulation FD Disclosure.


The information in this Current Report is being furnished pursuant to Item 7.01 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.


On January 28, 2013, Repros Therapeutics Inc., a Delaware corporation (the “Company”) issued a press release to revise the date for the expected clinical results from the first pivotal study, ZA-301, of Androxal® in the treatment of secondary hypogonadism, from Q2 2013 to Q3 2013. Included in this press release is an announcement that the Company would hold a conference call on Monday, January 28, 2013 at 8:00 a.m., Eastern Time, with the Teleconference Replay to be made available until February 4, 2013. The Company is furnishing herewith as Exhibit 99.1. to this Current Report on Form 8-K, a copy of the slideshow that was referenced during the conference call. These slides contain statements that are “forward-looking statements” subject to the cautionary statement about forward-looking statements set forth therein.



Item 9.01Financial Statements and Exhibits.





99.1Repros Therapeutics Slideshow






Pursuant to the requirements of the Securities Exchange Act of 1934 the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



  Repros Therapeutics Inc.
Date: January 28, 2013    
  By: /s/ Kathi Anderson
    Kathi Anderson
    Chief Financial Officer






Number   Description
99.1   Repros Therapeutics Slideshow